[CAS NO. 12192-57-3] Aurothioglucose
PRODUCTS SPECIFICATIONS [12192-57-3]
DESCRIPTION [12192-57-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 392.18 |
| Molecular Formula | C6H11AuO5S |
| SMILES | O[C@@H]1[C@](O[Au+][SH-]2)([H])C2O[C@H](CO)[C@H]1O |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC 50 : 65 nM (TrxR1) [1]
In Vitro
Aurothioglucose (0-100 μM, 24-72 h) inhibits TrxR1 activity in HeLa cell cytosol but has no effect on the viability of the cells
[1]
.
Aurothioglucose (0-30 μM, 6 h) exhibits very low cytotoxicity on cells
[1]
.
Aurothioglucose (0-20 μM, 24 h) combined with
Ebselen
(HY-13750) shows a strong synergistic effect, leading to Trx1 (thioredoxin 1) oxidation, reactive oxygen species (ROS) accumulation, and cell death
[1]
.
Aurothioglucose (0-100 μM, 3-12 days) inhibits p24 levels in OM10.1 and Ach2 cells, and inhibits HIV-1 replication in vitro
[2]
.
Aurothioglucose (0-25 μM, 12 days) increases the accumulation of metal gold in a dose-dependent manner
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | HeLa cells |
| Concentration: | 0, 5, 10, 50, 100 μM |
| Incubation Time: | 24, 48, 72 h |
| Result: | Inhibited TrxR activity by more than 90% at 100 μM in HeLa cells. Cell viability was unaffected by ATG treatment, even at 100 μM after 72 h. |
Western Blot Analysis [1]
| Cell Line: | HeLa cells |
| Concentration: | 0, 5, 10, and 100 μM |
| Incubation Time: | 24 h |
| Result: | Showed no significant oxidation of Trx1 or Trx2 in HeLa cells. |
Western Blot Analysis [2]
| Cell Line: | OM10.1, Ach2 cells |
| Concentration: | 0, 4, 10, 25 and 100 μM |
| Incubation Time: | 3, 6 or 12 days |
| Result: | Significantly inhibited p24 levels. After 12 days of incubation, the viability of cells treated with 10, 25 and 100 μM Aurothioglucose had decreased to 60% of the control. |
In Vivo
Aurothioglucose (25 mg/kg, i.p., single) significantly attenuates lung injury and enhances survival in a clinically relevant murine model of ARDS. The protective effects of Aurothioglucose are GSH dependent
[3]
.
Aurothioglucose (300 mg/kg, i.p., single) induces hypothalamic obesity in mice
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult male C3H/HeN mice (8-12 week, LPS/hyperoxia-exposed mice, inflammation/hyperoxia ARDS model) [3] |
| Dosage: | 25 mg/kg |
| Administration: | IP, single, at 12 h after intratracheal LPS administration |
| Result: | Significantly attenuated lung injury, increased lung GCLM expression and GSH levels, and decreased mortality. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 125 mg/mL ( 318.73 mM ; Need ultrasonic)
DMSO : 6 mg/mL ( 15.30 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5498 mL | 12.7492 mL | 25.4985 mL |
| 5 mM | 0.5100 mL | 2.5498 mL | 5.0997 mL |
| 10 mM | 0.2550 mL | 1.2749 mL | 2.5498 mL |
References
- [1] Du Y, et al. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J Biol Chem. 2012 Nov 2;287(45):38210-9.
- [2] Traber KE, et al. Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-alpha-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells. Int Immunol. 1999 Feb;11(2):143-50.
- [3] Britt RD Jr, et al. The thioredoxin reductase-1 inhibitor aurothioglucose attenuates lung injury and improves survival in a murine model of acute respiratory distress syndrome. Antioxid Redox Signal. 2014 Jun 10;20(17):2681-91.
- [4] Naruta E, et al. Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose. Exp Toxicol Pathol. 2001 Oct;53(5):393-8.
Synonyms
